| Code saturation versus meaning saturation: how many interviews are enough? MM Hennink, BN Kaiser, VC Marconi Qualitative health research 27 (4), 591-608, 2017 | 4315 | 2017 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1887 | 2021 |
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation International HIV Controllers Study Science 330 (6010), 1551-1557, 2010 | 1138 | 2010 |
| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... The lancet Respiratory medicine 9 (12), 1407-1418, 2021 | 728 | 2021 |
| Development of a definition of postacute sequelae of SARS-CoV-2 infection T Thaweethai, SE Jolley, EW Karlson, EB Levitan, B Levy, GA McComsey, ... Jama 329 (22), 1934-1946, 2023 | 499 | 2023 |
| Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study JF Okulicz, VC Marconi, ML Landrum, S Wegner, A Weintrob, A Ganesan, ... The Journal of infectious diseases 200 (11), 1714-1723, 2009 | 387 | 2009 |
| Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study N Crum-Cianflone, KH Hullsiek, V Marconi, A Weintrob, A Ganesan, ... Aids 23 (1), 41-50, 2009 | 346 | 2009 |
| HIV treatment adherence, drug resistance, virologic failure: evolving concepts J B. Nachega, V C. Marconi, G U. van Zyl, E M. Gardner, W Preiser, ... Infectious Disorders-Drug TargetsDisorders) 11 (2), 167-174, 2011 | 320 | 2011 |
| Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa VC Marconi, H Sunpath, Z Lu, M Gordon, K Koranteng-Apeagyei, ... Clinical infectious diseases 46 (10), 1589-1597, 2008 | 306 | 2008 |
| Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ... The Lancet infectious diseases 16 (5), 565-575, 2016 | 299 | 2016 |
| Increasing rates of obesity among HIV-infected persons during the HIV epidemic N Crum-Cianflone, MP Roediger, L Eberly, M Headd, V Marconi, ... Plos one 5 (4), e10106, 2010 | 277 | 2010 |
| Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE ε4/ε4 genotype accelerates HIV disease progression TD Burt, BK Agan, VC Marconi, W He, H Kulkarni, JE Mold, M Cavrois, ... Proceedings of the National Academy of Sciences 105 (25), 8718-8723, 2008 | 239 | 2008 |
| Anal cancers among HIV-infected persons: HAART is not slowing rising incidence NF Crum-Cianflone, KH Hullsiek, VC Marconi, A Ganesan, A Weintrob, ... Aids 24 (4), 535-543, 2010 | 238 | 2010 |
| Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility W He, S Neil, H Kulkarni, E Wright, BK Agan, VC Marconi, MJ Dolan, ... Cell host & microbe 4 (1), 52-62, 2008 | 231 | 2008 |
| The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States CS Kraft, AL Hewlett, S Koepsell, AM Winkler, CJ Kratochvil, LA Larson, ... Clinical Infectious Diseases 61 (4), 496-502, 2015 | 229 | 2015 |
| CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms MJ Dolan, H Kulkarni, JF Camargo, W He, A Smith, JM Anaya, T Miura, ... Nature immunology 8 (12), 1324-1336, 2007 | 208 | 2007 |
| HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database A Alonso, AE Barnes, JL Guest, A Shah, IY Shao, V Marconi Journal of the American Heart Association 8 (14), e012241, 2019 | 187 | 2019 |
| Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or … EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao, MLB Piruzeli, ... The Lancet Respiratory Medicine 10 (4), 327-336, 2022 | 178 | 2022 |
| Microvascular disease, peripheral artery disease, and amputation JA Beckman, MS Duncan, SM Damrauer, QS Wells, JV Barnett, ... Circulation 140 (6), 449-458, 2019 | 178 | 2019 |
| CTLA-4+ PD-1− memory CD4+ T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques CS McGary, C Deleage, J Harper, L Micci, SP Ribeiro, S Paganini, ... Immunity 47 (4), 776-788. e5, 2017 | 174 | 2017 |